Analytical Data
-
Gene name
MYEF2
- Application
-
Alternative Names
MST156
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9P2K5
-
Expression Region
372-576aa
-
Molecular Weight
37.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MYEF2, or Myelin Expression Factor 2, is a protein that plays a critical role in the regulation of myelin formation and maintenance in neural tissues. Research on MYEF2 has gained significant attention due to its potential implications in neurological disorders, such as multiple sclerosis and leukodystrophies, where myelin sheath integrity is compromised. Understanding the molecular mechanisms that govern MYEF2's function can provide insights into the processes of myelination and remyelination, which are crucial for nerve signal conduction and overall brain health. Moreover, MYEF2 has been implicated in cellular differentiation and proliferation within the central nervous system (CNS), making it a valuable target for therapeutic strategies aimed at repairing or regenerating damaged neural tissues. Recent studies have focused on characterizing the structure and interactions of MYEF2, unveiling its potential as a biomarker for myelin-related diseases and a target for drug development. Continued exploration of MYEF2's roles could lead to novel approaches in treating demyelinating diseases and enhancing recovery following neurological injuries.
